Roy Buchanan
Stock Analyst at JMP Securities
(3.82)
# 537
Out of 4,944 analysts
68
Total ratings
39.39%
Success rate
13.65%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $7.60 | +228.95% | 15 | Aug 12, 2025 | |
| DVAX Dynavax Technologies | Maintains: Market Outperform | $31 → $32 | $10.83 | +195.61% | 7 | Aug 8, 2025 | |
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $59 → $66 | $63.25 | +4.35% | 7 | Aug 8, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.49 | +301.15% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.50 | +81.82% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.06 | +88.68% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $1.70 | +958.82% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $64.85 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $1.94 | +106.19% | 3 | Feb 11, 2025 | |
| IRWD Ironwood Pharmaceuticals | Maintains: Market Outperform | $23 → $14 | $1.09 | +1,184.40% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $69.89 | -52.78% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $3.37 | +48.37% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $646.60 | -30.71% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $12.08 | +32.45% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.73 | - | 2 | Feb 16, 2023 |
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $7.60
Upside: +228.95%
Dynavax Technologies
Aug 8, 2025
Maintains: Market Outperform
Price Target: $31 → $32
Current: $10.83
Upside: +195.61%
Cidara Therapeutics
Aug 8, 2025
Maintains: Market Outperform
Price Target: $59 → $66
Current: $63.25
Upside: +4.35%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.49
Upside: +301.15%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.50
Upside: +81.82%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.06
Upside: +88.68%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $1.70
Upside: +958.82%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $64.85
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $1.94
Upside: +106.19%
Ironwood Pharmaceuticals
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.09
Upside: +1,184.40%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $69.89
Upside: -52.78%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $3.37
Upside: +48.37%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $646.60
Upside: -30.71%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $12.08
Upside: +32.45%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.73
Upside: -